ReviewNeuro-oncology practice2016
Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism.
Open access · bronzeAbstract readReview
In one paragraph
Review in Neuro-oncology practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Pooled it
- ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis.Brain and behavior · 2020Pooled it
- Anticoagulation Following Surgery for Glioblastoma: Case Report and Review of the Literature.Journal of neurological surgery reports · 2026Article
- Venous thromboembolism and secondary outcomes of bleeding and mortality in patients with gliomas: a multicenter cohort study.Frontiers in oncology · 2026Article
- Venous Thromboembolism in Patients with Glioblastoma: Molecular Mechanisms and Clinical Implications.Thrombosis and haemostasis · 2025Review
- Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review.Acta haematologica · 2025Review
- The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab.Journal of neuro-oncology · 2024Article
- Management of Thromboembolic Disease in Patients with Primary and Metastatic Brain Tumors.Current treatment options in oncology · 2023Review
- Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review.Neuro-oncology · 2023Article
- Catalytic Nanomedicine as a Therapeutic Approach to Brain Tumors: Main Hypotheses for Mechanisms of Action.Nanomaterials (Basel, Switzerland) · 2023Article
- Article
- Venous Thrombotic Events and Anticoagulation in Brain Tumor Patients.Current oncology reports · 2022Review
- Management of venous thromboembolism in high-grade glioma: Does low molecular weight heparin increase intracranial bleeding risk?Neuro-oncology · 2022Article
- Article
- Awake craniotomy for glioblastoma in COVID-19-positive patients and delivering the standard of care: illustrative case.Journal of neurosurgery. Case lessons · 2021Article
- Review
- Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism.Research and practice in thrombosis and haemostasis · 2020Article
- Incidence, Therapy, and Bleeding Risk-Cancer- Associated Thrombosis in Patients with Glioblastoma.Cancers · 2020Review
- Stroke Rate Increases Around the Time of Cancer Diagnosis.Frontiers in neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Michael Nabil KhouryDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Symeon MissiosDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Natasha EdwinDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Susmita SakrutiDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Gene BarnettDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Glen StevensDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
David M PeereboomDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Alok A KhoranaDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Manmeet S AhluwaliaDepartment of Neurooncology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida (M.N.K.); Department of Oncological Sciences, University of South Florida, Tampa, Florida (M.N.K.); Department of Neurosurgery, Louisiana State University, 1501 Kings Hwy, Shreveport, Louisiana (S.M.); Department of Internal Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (N.E.); Department of Hematology/Oncology, University Hospital, 11100 Euclid Avenue, Cleveland, Ohio (S.S.); Department of Neurosurgery,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B.); Department of Neurology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.S.); Department of Hematology and Oncology,Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (D.M.P., A.A.K., M.S.A.); Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio (G.B., G.S., D.M.P., M.S.A.).
Cleveland Clinic · USLouisiana State University in Shreveport · USUniversity of South Florida · USLouisiana State University · USMoffitt Cancer Center · USUniversity Hospitals of Cleveland · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a complication of glioblastoma. Anticoagulating patients with glioblastoma carries a theoretical risk of intracranial hemorrhage (ICH).
methodsWe performed a retrospective cohort study of consecutive glioblastoma patients (2007-2013) diagnosed with VTE.
resultsThe study population comprised of 523 glioblastoma patients of whom 173 (33%) had VTE events. Seventeen (10%) had ICH: 6 (35%) subdural hematomas and 11 (65%) intratumoral hemorrhages. In total, 4 patients with ICH required neurosurgical intervention. Enhancement in the area of subsequent intratumoral hemorrhage was noted in 9 of 10 with available pre-ICH scans. Multivariable regression did not show associations between ICH and tumor enhancement diameter or use of vascular-endothelial-growth-factor inhibitor. Fifteen (16%) patients receiving anticoagulation had ICH compared with 2 (2.6%) not receiving anticoagulation (
conclusionPatients with glioblastoma and VTE on anticoagulation have increased incidence of ICH. However, development of ICH was not associated with lower median survival from time of VTE. Intratumoral hemorrhage occurred within the enhancing portion of tumor; however, no relationship was identified between the development of ICH and (i) the median diameter of enhancement or (ii) type of anticoagulant used. However, patients with absence of enhancing tumor did not have intratumoral bleed, suggesting gross total resection may limit this adverse outcome. It is appropriate to initiate anticoagulation in glioblastoma patients with VTEs.
Indexed as
anticoagulationglioblastomaintracranial hemorrhagesearch termsvenous thromboembolism
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.